Batu Biologics | Date: 2015-05-07
The current application teaches methods and compositions useful for the treatment of cancer through administration of an antioxidant together with an immune stimulator at concentrations sufficient to augment antitumor immunity while simultaneously preventing inhibition of T cell function as a result of tumor secreted oxidative stress. Compositions such as toll like receptor agonists in combination with antioxidants are disclosed. In further embodiments, the application teaches the use of antioxidants to prevent immunotherapy associated oxidative stress, of which, one manifestation is vascular leak syndrome. In one specific embodiment, the application teaches the use of intravenous ascorbic acid as a means of reducing IL-2 associated toxicity.
News Article | June 18, 2015
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal. “The completion of this seed round of financing marks a critical inflection point in the development of our company and our lead program, ValloVax,” said Samuel C. Wagner, President and CEO of Batu Biologics. “Our strategy revolves around rapid clinical development, and we hope to soon realize the therapeutic potential of combining angiogenesis inhibition with the power of immunotherapy.” According to the American Cancer Society, an estimated 158,040 Americans are expected to die from lung cancer in 2015, accounting for approximately 27 percent of all cancer deaths. Batu Biologics recently filed an Investigational New Drug (IND) application (IND # 16296) with the FDA seeking to initiate a Phase I dose-escalation study for ValloVax™ in patients with non-small cell lung cancer. ValloVax is a polyvalent cancer vaccine that stimulates an immune response against the tumor-associated blood vessels, seeking to cut off the blood supply required for sustainable tumor growth. In preclinical testing, ValloVax was shown to inhibit new blood vessel formation in melanoma, breast and lung cancer mouse models. Batu Biologics has published preclinical data for ValloVax in The Journal of Translational Medicine, describing the feasibility and proposed methods of inducing immunity against the tumor endothelium as well as a summary of efficacy and safety studies conducted for the ValloVax™ platform. The article was co-authored by Dr. Amit Patel, Associate Professor, Department of Surgery at the University of Utah, Dr. Santosh Kesari, Director of Neuro-Oncology at the UC San Diego Moores Cancer Center, and Dr. Wei-ping Min, Professor, Department of Immunology, University of Western Ontario. “Batu Biologics would like to thank its investors, shareholders and collaborators who are supporting our efforts to bring our immune-therapeutic, ValloVax, into clinical trials,” said Alan Lewis, Chairman of Batu Biologics. “Harnessing and directing the immune system is changing the way we treat cancer. Our Team is focused on developing cutting-edge therapeutics that take a whole new approach to battling this terrible disease by blocking the mechanisms that feed the tumor. We aim to make a difference in the lives of patients in need of less toxic therapeutics.” Proceeds from this funding round will be dedicated to preparing the ValloVax platform for entry into the clinical setting, thus positioning Batu Biologics for a venture-backed Series A capital raise. Founded in 2013, Batu Biologics is an immuno-oncology company focused on the development and commercialization of novel therapies that target the Achilles Heel of cancer: the tumor blood vessels. Batu seeks to address the multidimensional nature of cancer by developing universal donor therapeutics that target multiple pathways concurrently to enhance efficacy and specificity. The company is headquartered in San Diego and maintains research facilities at JLABS@San Diego, located in San Diego’s Torrey Pines-area biotech cluster.
News Article | April 23, 2015
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced the issuance of United States patent # 8,999,349 covering composition of matter claims for its ImmXcyteTM immune-oncology peptide technology. ImmXcyteTM is a potent stimulator of immune responses, developed by University of California San Diego (UCSD), and exclusively licensed to Batu Biologics. Peer-reviewed publications by ImmXcyteTM inventor Dr. Davorka Messmer demonstrated the potency of this peptide drug candidate in activating the immune system to kill tumor cells1 through stimulation of the fundamental immunoregulatory pathway of the toll like receptor 4 (TLR-4)2. “The issuance of the current patent provides Batu a potent adjuvant that is useful at not only stimulating anticancer immunity in conjunction with our late stage preclinical product, ValloVax, but also an easy-to-manufacture reagent that can be outlicensed to vaccine developers targeting intracellular bacteria or viruses,” said Samuel Wagner, President and CEO of Batu Biologics. “Given the numerous scientific publications supporting the use of ImmXcyteTM and activators of the TLR-4 pathway as potent stimulators of immunity, we are confident that the issuance of the current patent positions Batu to engage in out-licensing discussions with parties in the space of immunotherapeutics.” ImmXcyteTM is derived from the high mobility group box (HMGB1) protein, which is one of the most potent immune stimulatory proteins that exists in the human body. Through years of research, Dr. Messmer, who has joined the Batu Biologics Scientific Advisory Board, discovered the specific portions of the protein that stimulate the immune response without overt side effects. “The issuance of this patent, combined with our ongoing work in developing ImmXcyteTM as a therapeutic, has led to development of our second pipeline drug candidate, which may have multiple utilities, not only in the space of oncology, but also in combating bacterial and viral infections,” said Dr. Hong Ma, Chief Scientific Officer of Batu Biologics. Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics has currently filed an Investigational New Drug Application (IND # 16296) for the initial indication of non-small cell lung cancer (NSCLC), and anticipates clinical approval to begin treating patients in Q3 of 2015.
News Article | June 22, 2015
The company intends to use the funds to advance its lead program ValloVax. Founded in 2013 and led by Samuel C. Wagner, President and CEO, and Alan Lewis, Chairman, Batu Biologics is developing its lead program ValloVax, a polyvalent cancer vaccine that stimulates an immune response against the tumor-associated blood vessels, seeking to cut off the blood supply required for sustainable tumor growth. In preclinical testing, ValloVax was shown to inhibit new blood vessel formation in melanoma, breast and lung cancer mouse models.
Batu Biologics | Entity website
Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVaxThe nine page pre-clinical work of Batu Biologics published by the Journal of Translational Medicine. Click on image above or here to download